Q-omics provides the consensus-scored SNORD113-1 profile across patient tissues and cancer cell-line models. SNORD113-1 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SNORD113-1 is differentially expressed in 1, with the highest sampling consensus in LUAD. Additionally, SNORD113-1 RNA expression shows 15,812 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, LUAD, and THYM as cancer lineages where SNORD113-1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORD113-1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORD113-1 survival associations across molecular data types. SNORD113-1 RNA expression shows survival associations in the most cancer types (10), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORD113-1 RNA expression–survival associations across cancer types. High SNORD113-1 expression shows unfavorable associations in MESO, KIRC, LUAD, HNSC and PAAD, but favorable associations in LAML. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SNORD113-1 RNA expression.
This table summarizes SNORD113-1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for SNORD113-1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORD113-1 shows higher tumor expression in LUAD. The LUAD box plot shows higher SNORD113-1 RNA expression in tumor versus normal tissue (log2 FC = +0.198, t-test p = .045).
This table shows molecular features associated with SNORD113-1 in patient tissues and cancer cell lines. In patient samples, SNORD113-1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
